Redcare Pharmacy NVXSWX:RDC 48 Forward PE Ratio is 472.87 as of Jun. 27, 2026. GuruFocus rates XSWX:RDC with a GF Score™ of 48/100 and a GF Value™ of CHF143.20 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 313 Healthcare Providers & Services companies, Redcare Pharmacy NV ranks worse than 99.04% on this metric.
Redcare Pharmacy NV (XSWX:RDC) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Redcare Pharmacy NV Forward PE Ratio Related Terms
Redcare Pharmacy NV Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Redcare Pharmacy NV's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Redcare Pharmacy NV Forward PE Ratio Chart
Redcare Pharmacy NV Annual Data
Trend
Forward PE Ratio
Redcare Pharmacy NV Quarterly Data
Forward PE Ratio
Redcare Pharmacy NV Forward PE Ratio Competitor Comparison
For the Pharmaceutical Retailers subindustry, Redcare Pharmacy NV's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Redcare Pharmacy NV Forward PE Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Redcare Pharmacy NV's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Redcare Pharmacy NV's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Redcare Pharmacy NV (XSWX:RDC) has a Forward PE Ratio of 472.87 as of Jun. 27, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Redcare Pharmacy NV and its competitors. According to the industry distribution chart, Redcare Pharmacy NV ranks #310 out of 313 companies in the Healthcare Providers & Services industry, placing it in the top 99%.
Is Redcare Pharmacy NV's Forward PE Ratio too high?
Redcare Pharmacy NV's current Forward PE Ratio is 472.87. The Healthcare Providers & Services industry median Forward PE Ratio is 17.75. Redcare Pharmacy NV's value of 472.87 is 2564.1% above this industry median. Based on the distribution chart, Redcare Pharmacy NV ranks #310 out of 313 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Redcare Pharmacy NV has a GF Score™ of 48/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Redcare Pharmacy NV's Forward PE Ratio compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Redcare Pharmacy NV ranks #310 out of 313 companies for Forward PE Ratio. This places Redcare Pharmacy NV in the lower half of its industry. The industry median Forward PE Ratio is 17.75. Redcare Pharmacy NV's value of 472.87 is 2564.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Healthcare Providers & Services company?
The median Forward PE Ratio among Healthcare Providers & Services companies is 17.75, based on 313 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Redcare Pharmacy NV's current Forward PE Ratio of 472.87 is 2564.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Redcare Pharmacy NV and its competitors. For the Healthcare Providers & Services industry, the median Forward PE Ratio is 17.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Redcare Pharmacy NV's current Forward PE Ratio is 472.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Redcare Pharmacy NV stock overvalued right now?
Based on GuruFocus' analysis, Redcare Pharmacy NV (XSWX:RDC) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF143.20, compared to a current price of CHF60.95 — trading 57.4% below its estimated fair value. The current Forward PE Ratio is 472.87 and 2564.1% above the Healthcare Providers & Services industry median of 17.75. Redcare Pharmacy NV's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Redcare Pharmacy NV (XSWX:RDC), the current Forward PE Ratio is 472.87 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Redcare Pharmacy NV (XSWX:RDC) Overvalued in 2026?
Based on GuruFocus' analysis, Redcare Pharmacy NV stock appears to be undervalued.
The current stock price of CHF60.95 is trading 57.4% below its estimated GF Value™ of CHF143.20.
GuruFocus considers Redcare Pharmacy NV to be Significantly Undervalued.
Key valuation signals for XSWX:RDC:
Forward PE Ratio: 472.87
GF Value™: CHF143.20 vs. price of CHF60.95 (57.4% below fair value)
Industry Position: 2564.1% above the Healthcare Providers & Services median (#310 of 313)
No single metric tells the full story. See the XSWX:RDC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Redcare Pharmacy NV is an online pharmacy business for prescription and nonprescription (over-the-counter) pharmaceuticals, beauty and personal care products (BPC) and food supplements. Besides OTC, nutritional supplements, beauty and personal care products as well as an extensive assortment of health-related products in all markets, the company also provides prescription drugs for customers in Germany, Switzerland and the Netherlands. It operates in two segments, namely DACH segment that includes sales in Germany, Austria and Switzerland; and the International segment that includes sales across Belgium, the Netherlands, France and Italy. The DACH segment accounts for the majority of the revenue.
48GF Score
Get the complete analysis for XSWX:RDC
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RDC has been successfully added to your 